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ALS is a fatal neurodegenerative disease characterized by a pro-
gressive loss ofmotor neurons and atrophy of distal axon terminals
in muscle, resulting in loss of motor function. Motor end plates
denervated by axonal retraction of dying motor neurons are
partially reinnervated by remaining viable motor neurons; how-
ever, this axonal sprouting is insufficient to compensate for motor
neuron loss. Activating transcription factor 3 (ATF3) promotes
neuronal survival and axonal growth. Here, we reveal that forced
expression of ATF3 in motor neurons of transgenic SOD1G93A ALS
mice delays neuromuscular junction denervation by inducing axo-
nal sprouting and enhancing motor neuron viability. Maintenance
of neuromuscular junction innervation during the course of the
disease in ATF3/SOD1G93A mice is associated with a substantial de-
lay in muscle atrophy and improved motor performance. Although
disease onset and mortality are delayed, disease duration is not
affected. This study shows that adaptive axonal growth-promoting
mechanisms can substantially improve motor function in ALS and
importantly, that augmenting viability of the motor neuron soma
and maintaining functional neuromuscular junction connections
are both essential elements in therapy for motor neuron disease
in the SOD1G93A mice. Accordingly, effective protection of optimal
motor neuron function requires restitution of multiple dysregu-
lated cellular pathways.
Amyotrophic lateral sclerosis (ALS) is an adult-onset de-generative disorder of motor neurons that manifests as
progressive paralysis and results in inevitable death, typically
within 5 y (1–3). Most cases of ALS are sporadic, with no ap-
parent familial history, whereas 10% of cases are inherited (2, 4,
5). Identifying the underlying dysregulated gene pathways and
pathological processes in ALS has been a major research focus
over the last decade. Mice that harbor a transgene-expressing
human cytosolic superoxide dismutase with an ALS-associated
mutation (designated hSOD1G93A) develop motor neuron dis-
ease that closely mimics the phenotype of both familial and spo-
radic ALS (6, 7).
Motor neuron cell death, accompanied by astrogliosis and
microglial activation, is the characteristic pathological feature in
ALS (8, 9). Additional pathological features include neuromus-
cular junction (NMJ) denervation, axonal degeneration, and
abortive collateral sprouting (10, 11). The combination of pro-
gressive motor neuron cell death and the retraction of axons
from NMJs together with an impaired ability of surviving intact
axons to generate compensatory axonal collateral sprouts results
in progressive irreversible muscle atrophy (2, 12, 13).
Activating transcription factor 3 (ATF3), a basic leucine zip-
per transcription factor, is induced under a variety of stress
conditions (14, 15). ATF3 transcriptional targets vary in different
cell types and conditions, resulting in diverse influences on cel-
lular phenomena, such as cell survival, proliferation, and death
(15, 16). In neurons (17), induction of ATF3 expression prevents
cell death and promotes neurite formation and elongation,
leading to enhanced nerve regeneration through transcriptional
induction of survival and growth-associated genes (18–26). Intact
adult motor neurons do not normally express ATF3. However,
after sciatic nerve injury, lumbar motor neurons induce and re-
tain ATF3 expression (27). ATF3 has not been detected in end
stage spinal cord samples of ALS mouse models or postmortem
samples of ALS patients (28–32). In the SOD1G93A ALS mouse
and rat models, ATF3 expression was detected in only a small
proportion of spinal motor neurons (33–36). However, it remains
unclear whether ATF3 induction in the motor neurons drives
prosurvival or even possibly, detrimental proapoptotic mecha-
nisms (33, 36). Because constitutive ATF3 expression in an ATF3
transgenic mouse model has no adverse phenotype (19) and
ATF3 has neuroprotective and regeneration-promoting actions in
diverse neurons, we examined the effect of constitutive ATF3
expression on disease phenotype in the ALS mouse model. Here,
we report that transgenic expression of ATF3 in adult motor
neurons of SOD1G93A mice altered the transcriptome to promote
motor neuron survival and maintain axonal integrity and NMJ in-
nervation. ATF3 expression in SOD1G93A mice resulted in a delay
in disease deterioration that manifested in delayed muscle atrophy,
improved muscle performance, and a small increase in lifespan.
Significance
This study reports on the beneficial effects of forcing high
expression of the transcription factor activating transcription
factor 3 (ATF3) in ALS. ALS is a noncurable adult-onset disease
that attacks motor neurons, resulting in paralysis and death.
ATF3 overexpression in motor neurons in an ALS mouse
model modifies gene expression and drives the neurons into
a prosurvival and proregenerative state, increasing motor
neuron survival and maintaining axonal connection with mus-
cle by promoting axonal sprouting. ATF3 overexpression results
in markedly improved muscle strength and function and delayed
disease onset but only slightly increased lifespan. Molecular
mechanisms that promote axonal sprouting could substantially
improve quality of life in ALS, although additional approaches
will be required to overcome progressive motor neuron
deterioration.
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Results
ATF3 Promotes Motor Neuron Survival in ATF3/SOD1G93A Mice. To
address the effect of forced ATF3 expression on motor neuron
survival in the SOD1 mutant mice, ATF3 transgenic mice (19) were
crossed with hSOD1G93A transgenic mice that harbor the mutant
gene at high copies (6), and their progeny was analyzed. These
ATF3 transgenic mice express the ATF3 transgene under control
of the thy1.2 promoter (19), which drives transgene expression
specifically in postnatal neurons (37). To exclude transgene ex-
pression variability, two independent ATF3 transgenic founder lines
that express ATF3 abundantly in most spinal motor neurons were
crossed with SOD1G93A mice and generated identical results.
Progressive motor neuron cell death is a hallmark of ALS.
Motor neuron survival was quantified at 60 d of age (a pre-
symptomatic stage), 90 d of age (when disease onset is apparent),
and 120 d of age [by which time the mice show clear muscle
weakness but are not at end stage (130–140 d of age)]. Large
lumbar motor neurons with a cell body area of ≥450 μm2 were
quantified using the neuronal marker NeuN. Thus, only the large
α-motor neurons most vulnerable to cell death in ALS (2, 38, 39)
were quantified, and the γ-type motor neurons that are resistant
to the disease were excluded. In SOD1G93A littermates at the
presymptomatic stage, no motor neuron cell death was detected,
but by the time of disease onset, only 45.8% of motor neurons
had survived, with 19.3% of motor neurons surviving at 120 d of
age (Fig. 1 A and D–F). In contrast, motor neuron survival in the
ATF3/SOD1G93A double transgenic mice was substantially higher;
78.6% and 57.6% of the motor neurons survived at 90 and 120 d,
respectively (Fig. 1 A and H–J).
Less than 10% of large motor neurons in SOD1G93A mice
induced endogenous ATF3 expression, which was detected by
double immunostaining for ATF3 and NeuN (Fig. 1 B–F). As
anticipated, in the presence of the ATF3 transgene, 79.71 ±
2.14% and 77.53 ± 2.8% of the motor neurons were ATF3-
positive in ATF3/SOD1G93A and ATF3/WT mice, respectively
(Fig. 1 B and G–J). The fraction of non-ATF3–expressing motor
neurons (∼20%) in ATF3/WT transgenic mice and in ATF3/
SOD1G93A mice was similar. This fraction in ATF3/SOD1G93A
mice remained unaltered over time (Fig. 1 B and H–J). A cell-
autonomous mechanism of ATF3 action would be expected to
enhance the survival of only ATF3-positive neurons and thus,
lead to a decrease in the ATF3-negative fraction over time.
However, the lack of change in this fraction suggests that the
beneficial influence of ATF3 may also be mediated by non-cell-
autonomous actions that protect neighboring motor neurons that
do not express ATF3 (Fig. 1 B and H–J). For example, a non-
cell-autonomous action could be achieved if ATF3 induces the
expression of secreted factors that then exert the protective ac-
tion on the non-ATF3–expressing cells or because of reduced
neuroinflammation caused by the increased neuronal survival.
ATF3 Delays the Loss of Axonal Integrity in ATF3/SOD1G93A Mice. Analy-
sis of lumbar L5 ventral roots (Fig. 2) revealed axonal damage early
on at the presymptomatic stage (60 d) in SOD1G93A mice. Large-
caliber α-axons with a diameter >3.5 μm degenerate in ALS. This
degeneration is observed in the ventral root as a decline in di-
ameter size. A continuous decline in large axons with a corre-
sponding increase in the number of small axons was observed
over time in SOD1G93A mice (Fig. 2). In contrast, significant
axonal damage in the ventral roots was detected only at 120 d in
ATF3/SOD1G93A mice (Fig. 2F). The most extreme differences
were detected at 90 d, at which time ATF3/SOD1G93A axons
remained intact; by contrast, in SOD1G93A mice at this time
point, there was an increase of 51% in small-caliber axons be-
cause of the rapid degeneration of SOD1G93A large-caliber axons
(Fig. 2 C–F).
ATF3 Delays NMJ Denervation and Muscle Atrophy. Evaluation of
NMJs in the gastrocnemius muscle of SOD1G93A mice revealed
denervation as early as 60 d of age, with only 70.5 ± 4.6% of the
NMJs remaining innervated at this time (Fig. 3 C and K). De-
nervation of the NMJs accelerated in SOD1G93A mice as the
disease progressed, and it was accompanied by a collapse of
the NMJ structures, which were revealed by a reduction in the
number of pretzel-shaped NMJs (Fig. 3L). NMJ collapse was
apparent at 90 d in SOD1G93A mice and rapidly accelerated, with
only 56.6% of NMJs retaining their normal morphology in the
gastrocnemius muscle at 120 d (Fig. 3 L and I).
The rate of NMJ denervation extrapolated from Fig. 3K does
not include the acceleration in NMJ collapse. Evaluation of the
actual percent of NMJ denervation, which takes into account the
loss of NMJs, reached 69.7 ± 5.2% at 120 d in SOD1G93A mice
(Fig. 3M). In contrast, denervated NMJs were detected only at
120 d of age in ATF3/SOD1G93A mice; even then, 83.1 ± 3.4% of
the NMJs remained innervated, and there was no apparent NMJ
collapse (Fig. 3 H, J, K, and M). No difference in the extent of
NMJ innervation between WT and ATF3/WT littermates was
detected, indicating that ATF3 in WT mice did not induce hy-
perinnervation under normal conditions (Fig. 3 A, B, and K).
Measurements of gastrocnemius muscle weight in the SOD1G93A
mice revealed muscle wasting (24% weight loss) at the pre-
symptomatic stage (60 d), correlating with the early NMJ
denervation detected at this time (Figs. 3 and 4). The decline
in muscle mass in SOD1G93A mice advanced over time; weight
Fig. 1. Forced ATF3 expression promotes motor neuron survival. (A) Lumbar
ventral horn motor neurons immunostained for the neuronal marker NeuN
with an area ≥ 450 μm2 were quantified in the SOD1G93A compared with
ATF3/SOD1G93A mice at 60, 90, and 120 d. A significant difference in the
number of surviving motor neurons was identified. Data are presented as
mean ± SEM with n = 5 mice per group per time point. **P < 0.01; ***P <
0.001 by ANOVA with Bonferroni postanalysis. A significant difference in the
number of motor neurons in ATF3/SOD1G93A at 90 and 120 d relative to 60 d
was also detected. #P < 0.05; ##P < 0.001 by ANOVA with Bonferroni post-
analysis. (B) A significant difference was found in the percentage of ATF3-
positive motor neurons in ATF3/SOD1G93A compared with SOD1G93A mice at
all time points (P < 0.0001 by ANOVA). No difference in the proportion of
ATF3-positive motor neurons was detected within each group over time (P >
0.05 by ANOVA with Bonferroni postanalysis). ATF3 expression in control WT
and ATF3/WT mice at age 120 d is presented. (C–J) Representative merged
images of motor neurons double stained for NeuN (green) and ATF3 (red)
(nonmerged images are presented in Fig. S1). (Scale bar: 50 μm.) (D and E)
Some endogenous ATF3 induction is detected in the SOD1G93A mice (red arrows
and Inset). (G–J) Motor neurons that do not express ATF3 in the ATF3/WT
and ATF3/SOD1G93A mice are marked by a white arrow.
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reduction in the gastrocnemius muscle was 35% and 55.5% at 90
and 120 d, respectively, compared with WT mice (Fig. 4). In
contrast, ATF3/SOD1G93A mice preserved muscle mass and
only showed muscle wasting at 120 d of age (20%) (Fig. 4).
As the disease progressed, measurement of end plate in-
nervation in SOD1G93A mice showed that motor axons retracted
from the NMJs concomitantly with the development of muscle
atrophy, which preceded motor neuron cell body death (Fig. 5 A
and B). Such axonal dying back phenomenon is well-character-
ized in both human ALS and mouse disease models (12).
However, although some motor neuron cell death was already
apparent in ATF3/SOD1G93A mice at 90 d of age, NMJs de-
nervation was not detected in these mice until 120 d (Fig. 5 A
and C). This discrepancy suggests that, as NMJs are dennervated
by motor neuron loss, they become reinnervated by sprouts ex-
tended from the intact axons of surviving motor neurons, con-
tributing to the delay in muscle atrophy (Fig. 5B). Extension of
collateral and terminal axonal sprouts is detected in ALS disease,
but this sprouting process is usually unable to compensate for
loss of axonal connections with muscle (11). In SOD1G93A mice,
quantification of terminal sprouts in the gastrocnemius muscle
detected no sprouting at 60 d. The amount of terminal sprouting
at 90 and 120 d was similar, with no increase over time (Fig. 5D).
In ATF3/SOD1G93A mice, terminal sprouting was also first de-
tected at 90 d and similar to the sprouting in SOD1G93A mice.
However, at 120 d, the degree of terminal sprouting was signif-
icantly higher in ATF3/SOD1G93A mice than SOD1G93A mice
(Fig. 5D–G). These data suggest that ATF3 promotes the capacity
to form and maintain terminal axonal sprouts in SOD1 mutant
mice to maintain NMJ innervation and prevent muscle atrophy.
ATF3 Delays Motor Deficits and Disease Onset in ATF3/SOD1G93A Mice.
We next tested whether the beneficial effects of ATF3 on motor
neuron survival and axonal connectivity with muscle identified in
this study had an impact on muscle performance and disease
progression. ATF3/SOD1G93A double transgenic mice displayed
increased muscle strength compared with SOD1G93A litter-
mates as determined by the hind limb grip strength assay (Fig.
6A). The improved motor performance in ATF3/SOD1G93A mice
directly reflected an impact of the ATF3 transgene on the dis-
ease; the ATF3 transgene did not enhance muscle strength in
ATF3/WT transgenic littermates compared with WTs.
Onset of the disease in ATF3/SOD1G93A mice was delayed
by an average of 11.3 d. Age at onset was 91.72 ± 2.44 d in
SOD1G93A mice compared with 103.1 ± 2.2 in ATF3/SOD1G93A
double transgenic mice (P < 0.01 by Kaplan–Meier log rank test)
(Fig. 6B). Similarly, mean survival in ATF3/SOD1G93A mice was
prolonged by 7.7 d. The average ages at death were 137.2 ± 1.4
and 144.9 ± 2.1 d in the SOD1G93A and ATF3/SOD1G93A mice,
respectively (P < 0.01 by Kaplan–Meier log rank test for survival)
(Fig. 6C). However, no difference was identified in disease
Fig. 2. Axonal integrity is maintained in the ATF3/SOD1G93A mice. (A–D)
Representative cross-section images of L5 ventral roots isolated from WT,
ATF/WT, SOD1G93A, and ATF3/SOD1G93A mice at 90 d of age. (Scale bar: 50
μm.) (E and F) Quantification of axonal size per ventral root. Note that there
is a reduction in the percentage of large-caliber axons and a concurrent
increase in the percentage of small-caliber axons in the SOD1G93A mice
compared with the ATF3/SOD1G93A mice (n = 6–9 mice per group per time
point). *P < 0.05; **P < 0.001; ***P < 0.0001 by ANOVA with Bonferroni
postanalysis. The total mean ± SEM values of axons counted per ventral root
in SOD1G93A mice at 60, 90, and 120 d were 904 ± 24.56, 677.7 ± 23.08, and
586.54 ± 28.26, respectively. The total mean ± SEM values of axons counted
per ventral root in ATF3/SOD1G93A mice at 60, 90, and 120 d were 781.83 ±
30.81, 803 ± 31.85, and 653.81 ± 9.27, respectively. In WT and ATF3/WT, the
numbers of axons were 911.6 ± 14.99 and 980.5 ± 58.67, respectively. (E)
Distribution of axonal diameter size in SOD1G93A compared with ATF3/SOD1G93A
mice at 90 d of age is presented. (F) Percent of small-diameter axons (Sm; 0–
3.5 μm) compared with large-diameter axons (Lg; 3.5–19 μm) per ventral
root. Control (Ctrl) WT and ATF3/WT mice were 120 d of age.
Fig. 3. Innervation of the NMJ is maintained in ATF3/SOD1G93A mice. (A–M)
Immunostaining with α-bungarotoxin (green) to label the NMJs in the gas-
trocnemius muscle and antineurofilament (red) to mark innervating axons
reveals severe NMJ denervation and NMJ collapse in SOD1G93A mice com-
pared with ATF3/SOD1G93A mice that worsens as the disease progresses. Only
NMJs with a pretzel-shaped morphology were quantified. Nonmerged
images are presented in Fig. S2. (Scale bar: A–H, 20 μm; I and J, 50 μm.) (I)
Arrows show collapsed NMJs. (K–M) n = 9 mice per group per time point. (K)
This graph represents the percent of innervated NMJs out of the total
number of intact pretzel-shaped NMJs within each group. *P < 0.01; **P <
0.001; ***P < 0.0001 by ANOVA with Bonferroni postanalysis. (L) There is
a decline in the number of pretzel-shaped NMJs in the SOD1G93A mice over
time. *P < 0.05; ***P < 0.0001 by ANOVA with Bonferroni postanalysis. No
difference in the number of NMJs in ATF3/SOD1G93A over time and com-
pared with WT was observed (P > 0.05). (M) Actual percent denervation
represents the percent of denervated NMJs in each group relative to the
total number of NMJs in WT mice at 90 d of age. **P < 0.001; ***P < 0.0001 by
ANOVA with Bonferroni postanalysis.
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duration between the groups (P > 0.05). Although ATF3 ex-
pression was sufficient to modestly delay the onset of the disease
and consequently, prolong survival, disease duration was not
extended. Nonetheless, as the disease progressed and SOD1G93A
mice reached end stage, they were weak and largely immobile,
whereas ATF3/SOD1G93A mice were in much better health.
They were grooming and exploring their cages (Movies S1 and
S2), illustrating the marked beneficial effects of ATF3 on muscle
performance as the disease progressed.
Fig. 4. ATF3 expression in SOD1G93A mice delays muscle atrophy. (A) Repre-
sentative image of the gastrocnemius muscle showing delayed muscle atrophy
in ATF3/SOD1G93A compared with SOD1G93A mice at 120 d of age. (B and C)
Muscle wasting was calculated by measurement of the gastrocnemius muscle
weight in male mice littermates (the same trend was found in female mice).
Data are presented in grams as mean ± SEM (n = 4–6 per group). *P < 0.01;
**P < 0.001; ***P < 0.0001 by ANOVAwith Bonferroni postanalysis. (C) Percent
muscle atrophy was calculated relative to WT mice.
Fig. 5. Changes in architecture of the motor unit induced by SOD1G93A are
attenuated by ATF3 transgene coexpression. (A) Comparison of progressive
changes in percentages of remaining motor neurons (black diamonds), large
axons (blue squares), innervated NMJs (extrapolated from the actual de-
nervation data in Fig. 3M) (green triangles), and weight (red circles) in (Left)
SOD1G93A and (Right) ATF3/SOD1G93A mice. In SOD1G93A mice, all parameters
rapidly decline over time. By contrast, in ATF3/SOD1G93A mice, all four
parameters are indistinguishable from WT at 60 d, and only numbers of
largemotor neurons declined by 90 d. At 120 d, all parameters are improved in
ATF3/SOD1G93A mice compared with SOD1G93A counterparts. Arrow highlights
the 90-d time point at which ATF3/SOD1G93A mice clearly show a decline in
numbers of surviving motor neurons without a decline of innervated NMJs or
other parameters. (B and C) A schematic model of the disease course illustrates
the dying back phenomenon in SOD1G93A mice and induction of collateral
sprouts in ATF3/SOD1G93A mice as a mechanism to maintain maximal NMJ in-
nervation. Intact motor neurons and axons are in purple/blue. Diseased motor
neurons are indicated with white specks, and degenerating axons are indicated
with white and black. New collateral axonal sprouts are yellow; intact muscle is
red, and NMJs are green. (D) Terminal sprouts were determined when the nerve
extended beyond the acetylcholine receptor (AChR) clusters in the innervated
NMJ at any direction. Sprouting is presented as the percent of NMJs with sprouts
relative to the total number of innervated NMJs in each group. Increased
sprouting is detected at 120 d in ATF3/G93A comparedwith G93Amice. *P< 0.01
by ANOVA with Bonferroni postanalysis (n = 4–5 mice per time point). (E–G)
Immunostaining with α-bungarotoxin (green) to label NMJs in the gastrocnemius
muscle and antineurofilament (red) to mark innervating axons reveals sprouting
at the NMJ in ATF3/G93A mice. The terminal sprout is indicated with an arrow.
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Discussion
This study shows that forced expression of the transcription
factor ATF3 in SOD1G93A ALS mice slows the loss of motor
neurons, delays terminal axonal atrophy, and augments axonal
sprouting by driving the motor neurons into a prosurvival and
regenerative state. In the ALS mouse model, forced ATF3 ex-
pression modifies the cell transcriptome (Figs. S3, S4, and S5) to
support compensatory axonal sprouting and neuronal survival.
At 90 d, the ATF3/SOD1G93A mice showed no loss of NMJ in-
nervation, despite some motor neuron loss, suggesting that de-
nervated NMJs in ATF3/SOD1G93A mice are rapidly reinnervated
by terminal and collateral sprouts extending from neighboring intact
motor neurons that are in a proregenerative state. Moreover, at this
age, the ATF3/SOD1G93A mice showed little or no loss of muscle
mass and showed improved muscle strength relative to SOD1G93A
mice, such that the overall health of the animals was remarkably
improved. However, although disease onset and death were
slightly delayed, disease duration was not extended, indicating
that induction of an intrinsic growth state in SOD1 mutant motor
neurons by ATF3 was not sufficient to halt disease progression.
Although ATF3-dependent compensation improved motor
neuron viability, axonal dynamics, and motor performance, it
did not arrest the ongoing motor neuron loss sufficiently to
prevent death.
It is well-established that terminal axonal degeneration with
NMJ denervation is an early component of motor neuron disease
in ALS (12, 40, 41) (Fig. 5). Whereas intact motor neurons un-
dergo distal axonal sprouting, this remodeling is insufficient to
innervate neighboring denervated end plates and compensate for
motor neuron loss, leading to progressive paralysis and death
(11). Regardless of whether these deficits in axonal innervation
or capacity to sprout arise as a consequence of events in the
soma, such as excitotoxicity, endoplasmic reticulum stress, or
mitochondrial pathology, or distally at peripheral nerve endings,
it is evident from this study that the functional reserve provided
by surviving motor neurons is enhanced by mechanisms that in-
crease their axonal integrity, growth, and sprouting and thereby,
maintain maximal connectivity with muscle.
The functional importance of the response of the axon to
motor neuron pathology is illustrated by experimental paradigms
that prevent death of the motor neuron soma. Three different
experimental manipulations can delay motor neuron soma death
in SOD1 mutant ALS mice: overexpression of the antiapoptotic
protein Bcl-2, KO of the proapoptotic Bax protein, and double
KO of BAX and BAC (42–44). However, even in the BAX/BAC
double KO mice (42), in which a substantial delay in motor
neurons cell death is observed, axonal integrity is not preserved
to the same degree, and the motor axon terminals continue to
gradually die back from the NMJ. Despite the substantial pre-
servation of motor neuron soma achieved in these mouse model
experiments, motor neuron survival alone does not prevent
axons from degenerating.
The strong propensity for axonal degeneration in SOD1 mu-
tant ALS mice is shown in an additional model. In Wlds mice,
a unique fusion protein of ubiquitin conjugation factor E4B and
nicotinomide mononucleotide adenylyltransferase 1 dramatically
delays Wallerian degeneration after nerve injury and protects
against axonal degeneration in several neuropathies and neuro-
degenerative models. However, when it is bred into the SOD1G93A
mice, the Wlds gene fails to block axonal degeneration (45, 46).
The molecular events controlled by Wlds expression that blunt
axonal degeneration do not suffice to slow axonal degeneration
triggered by mutant SOD1 protein. From this perspective, it is
striking that, by contrast, the transcription factor ATF3 sub-
stantially augments axonal protection and sprouting, at least
through ∼90–100 d.
Mechanisms that act to protect only one compartment, either
the motor neuron soma or the axons, do not seem sufficient to
preserve a functional motor unit in ALS (42–46). The impor-
tance of both maintaining axonal connectivity with the muscle
and protecting the motor neurons from cell death for preserva-
tion of a functional motor unit is clearly illustrated in this study.
The modest degree of muscle denervation and atrophy at 120 d
in ATF3/SOD1G93A mice is comparable with the denervation
detected in SOD1G93A mice 2 mo earlier (at 60 d of age).
However, muscle performance is not maintained to the same
extent. This difference implies that newly collaterally innervated
NMJs, although sufficient to prevent muscle atrophy, do not
maintain full muscle strength as the disease progresses, which
may reflect the limited function of collateral sprouts relative to
normal inputs. The preservation of large α-motor axon integrity
found in this study is crucial for maintaining muscle mass and
function, but the fact that axonal damage and progression of
motor neuron cell death are observed in ATF3/SOD1G93A mice
at 120 d suggests that deleterious processes continue to impair
motor neuron function over time and secondarily, may com-
promise the axonal maintenance, dynamic axonal sprouting, and
remodeling that are promoted by ATF3. Future studies, including
longitudinal observations on motor neuron survival, axonal
remodeling, and NMJ function in ATF3/SOD1G93A and ATF3/
SOD1G93A mice with knockdown of the BAX/BAC proapoptotic
genes, may help tease out why the beneficial influence of ATF3
on disease onset and lifespan is so modest relative to the sub-
stantial effect that it has on reducing neuronal loss, axonal
damage, and denervation of the NMJ. These studies may also
help identify key disease-inducing pathways that are resistant to
ATF3-mediated transcriptional changes. However, the early
benefits of ATF3 on overall function are substantial and if
they could be translated into patients, might dramatically
improve quality of life. Additional interventions would be
required to slow significantly the inexorable ATF3-resistant
cell death.
Transcription factors control the expression of many genes,
and therefore, they serve as good candidates to govern the syn-
chronization and coordination between the many different gene
pathways required to achieve regeneration and neuronal sur-
vival. ATF3, a basic leucine zipper transcription factor (14),
regulates gene expression either directly by binding the DNA as
a homodimer or heterodimer or indirectly by sequestering acti-
vators and repressors, and thus, its transcriptional targets depend
on the specific cellular milieu. Neuronal expression of ATF3
induced favorable transcriptional changes in the ventral horn of
ATF3/SOD1G93A mice (Figs. S3, S4, and S5), including reduced
induction of neuroinflammatory and apoptotic gene pathways,
improved nerve transmission, and enhanced expression of gene
pathways involved in cytoskeleton organization, axon guidance,
and neurogenesis. These findings suggest that ATF3 modifies the
intrinsic growth state of the motor neurons to enable axonal
Fig. 6. ATF3 neuronal expression prolongs survival and delays motor deficits
in the SOD1 mutant mice. (A) Hind limb grip strength analysis for WT, ATF3/
WT, SOD1G93A, and ATF3/SOD1G93A mice. Data are mean ± SEM. *P < 0.05;
***P < 0.001 by repeated measures ANOVAwith Bonferroni postanalysis (n =
30 mice per group). (B and C) ATF3/SOD1G93A mice display delayed onset of
disease and prolonged survival (P = 0.0026 and P = 0.0013, respectively, by
Kaplan–Meier log rank test for survival; n = 29 mice per group).
1626 | www.pnas.org/cgi/doi/10.1073/pnas.1314826111 Seijffers et al.
sprouting and remodeling in the ATF3/SOD1G93A mice (Figs. S4
and S5). Interestingly, the set of genes that is uniquely up-reg-
ulated in ATF3/SOD1G93A clusters in pathways that support
axonal myelination and nerve transmission (Fig. S5), supporting
a role for ATF3 in maintaining axonal integrity and function and
thereby, retaining muscle mass and function.
This study (i) supports the view that neuroprotection to im-
prove motor neuron viability will be required to slow disease
progression and (ii) shows, in addition, that, to counteract motor
neuron loss, it may also be critical to induce regenerative
mechanisms that reduce terminal axonal degeneration and en-
hance compensatory axonal sprouting and functional reinner-
vation of denervated NMJs. Because the cell survival and
regenerative mechanisms that ATF3 induces are not sufficient to
completely repair motor neurons in ALS, complementary pro-
tective mechanisms that target the multiple dysregulated cellular
pathways will be required for full restitution, further reflecting
the complexity of the disease.
Materials and Methods
ATF3 transgenic mouse lines (19) that constitutively express ATF3 in neurons,
including spinal motor neurons, were crossed with high-copy number
SOD1G93A transgenic mice (6) (stock number 002726; Jackson Laboratories).
Protocols for the behavioral examinations are described in SI Materials and
Methods. Muscle, motor neuron, ventral root, and NMJ analyses, including
staining protocols and antibodies used, and additional methods are pro-
vided in SI Materials and Methods.
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